GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers
G. Bianco, M. Coto Llerena, J. Gallon, S. Taha-Mehlitz, V. Kancherla, M. Konantz, S. Srivatsa, H. Montazeri, F. Panebianco, M. De Menna, V. Paradiso, C. Ercan, A. Dahmani, E. Montaudon, N. Beerenwinkel, , S. Piscuoglio
This study identifies GATA3 and MDM2 as synthetic lethal in ER-positive breast cancers, showing MDM2 inhibition can target GATA3-deficient tumors via the PI3K/Akt/mTOR pathway.
bioRxiv · May 18, 2020Cancer Biology